SCHEMBL24309588

SCHEMBL24309588

CC(=O)Nc1cccc(S(=O)(=O)Nc2nc(Oc3ccccc3)cc(-c3ccccc3C)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.49
▸ PLA2G7 Q13093 2/20 0.44
▸ ATM Q13315 1/20 0.43
▸ LMNA P02545 5/20 0.42
▸ MAPT P10636 3/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ TSHR P16473 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ PIK3C2B O00750 1/20 0.41
▸ PIK3C2G O75747 1/20 0.41
▸ IDH1 O75874 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566945 1.00 PKM (0.49) PKMPLA2G7ATMLMNAMAPT
SCHEMBL26807087 0.92 PKM (0.50) PKMPLA2G7ATMLMNAMAPT
SCHEMBL26807176 0.88 PLA2G7 (0.46) PKMPLA2G7ATMLMNAMAPT
SCHEMBL26810957 0.86 TSHR (0.54) PKMLMNAMAPTALDH1A1KMT2A
SCHEMBL24309603 0.84 POLB (0.45) PKMLMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL26811070 0.82 PLA2G7 (0.46) PLA2G7LMNAMAPTMEN1KMT2A
SCHEMBL24309602 0.80 PGR (0.56) LMNAMAPTALDH1A1MEN1KMT2A
SCHEMBL29568117 0.80 PGR (0.56) LMNAMAPTALDH1A1MEN1KMT2A
SCHEMBL24309592 0.80 NPC1 (0.37) LMNAMAPTALDH1A1MEN1MAPK1
SCHEMBL26807160 0.80 CA12 (0.41) LMNAMAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B PKM 2127/4885PLA2G7 741/4885ATM 1808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback